Top Page
Opus Genetics
(NASDAQ:IRD)
Opus Genetics (IRD) vs. SPDR S&P 500 ETF (SPY)
Opus Genetics Business Overview & Revenue Model
Opus Genetics Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| Gross Profit | 14.14M | 10.99M | 19.05M | 39.85M | 589.00K |
| EBITDA | -38.60M | -57.52M | -9.97M | 18.22M | -56.69M |
| Net Income | -49.59M | -57.53M | -9.99M | 17.89M | -56.69M |
Balance Sheet | |||||
| Total Assets | 50.24M | 36.86M | 53.95M | 48.99M | 26.08M |
| Cash, Cash Equivalents and Short-Term Investments | 45.09M | 30.32M | 50.52M | 42.68M | 24.75M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 538.00K |
| Total Liabilities | 34.90M | 30.14M | 4.04M | 2.75M | 3.85M |
| Stockholders Equity | 15.35M | 6.72M | 49.91M | 46.24M | 22.22M |
Cash Flow | |||||
| Free Cash Flow | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Operating Cash Flow | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Investing Cash Flow | 0.00 | 1.21M | 0.00 | 0.00 | -100.00K |
| Financing Cash Flow | 50.02M | 4.19M | 8.98M | 3.79M | 27.61M |
Opus Genetics Technical Analysis
Opus Genetics Risk Analysis
Opus Genetics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $341.52M | -25.22 | -452.26% | ― | 74.60% | -58.14% | |
54 Neutral | $237.68M | -3.06 | -131.71% | ― | -100.00% | 79.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $425.81M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
50 Neutral | $219.43M | -0.39 | ― | ― | -63.96% | -28.50% | |
50 Neutral | $86.26M | -1.25 | -209.00% | ― | ― | 40.22% | |
47 Neutral | $261.67M | -1.90 | -63.74% | ― | 946.61% | -11.30% |
Opus Genetics Corporate Events
On February 13, 2026, Opus Genetics, Inc. entered into a securities purchase agreement with certain investors for a private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, which closed on February 18, 2026, raising approximately $25.0 million at $3.39 per share. The proceeds are earmarked to advance the company’s gene therapy clinical programs and general purposes, with the preferred shares set to automatically convert into common stock on a one-for-one basis following stockholder approval of an increase in authorized common shares, subject to ownership limits.
In connection with the financing, Opus executed a registration rights agreement on February 18, 2026, committing to register the resale of common shares issuable upon conversion of the Series B Preferred Stock, with a filing deadline for the initial registration statement set no later than April 19, 2026. The company also filed a Certificate of Designation in Delaware to establish the rights of the Series B Preferred Stock, which carries as-converted dividend rights, limited protective voting rights, parity with common stock in liquidation, and conversion caps designed to prevent any holder from exceeding a specified beneficial ownership threshold.
The most recent analyst rating on (IRD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Opus Genetics, a gene therapy developer targeting rare inherited retinal diseases with a diversified AAV-based pipeline spanning seven indications and two clinical-stage programs, is positioning itself as a focused player in the IRD space with a portfolio strategy designed to generate multiple clinical milestones and capital-efficient development. On January 15, 2026, the company’s management was scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference, outlining its “string of pearls” portfolio approach, the advancement of its clinical and preclinical IRD assets, and its reliance on cost-effective programs, non-dilutive and voucher-related funding, and partnered strategic financial assets, framing a development model that could broaden its patient reach and potentially streamline regulatory and commercial paths for its gene therapy candidates.
The most recent analyst rating on (IRD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
On January 8, 2026, Opus Genetics highlighted its 2025 operational progress and outlined key milestones expected in 2026, underscoring the maturation of its multi-asset ophthalmic pipeline and strengthening financial position. In 2025, the company advanced two lead gene therapies—OPGx-BEST1 for BEST1-related inherited retinal disease, which began dosing patients in a Phase 1/2 trial, and OPGx-LCA5 for Leber congenital amaurosis, which produced positive Phase 1/2 safety and efficacy data in adults and pediatric patients and is being advanced into an adaptive pivotal Phase 3 study. The pipeline benefited from multiple regulatory designations for OPGx-LCA5, including Rare Pediatric Disease, Orphan Drug and RMAT status, while OPGx-BEST1 is being positioned for similar regulatory pathways, and preclinical IRD programs targeting RHO, CNGB1, MERTK, RDH12-LCA and NMNAT1 moved toward first-in-human studies with support from patient advocacy partnerships and non-dilutive funding. Opus also submitted a supplemental new drug application for Phentolamine Ophthalmic Solution 0.75% for presbyopia and continued a pivotal Phase 3 trial (LYNX-3) in keratorefractive patients experiencing low-light visual disturbances. Financially, as of September 30, 2025, Opus held $30.8 million in cash and equivalents and subsequently raised about $23 million in a registered direct equity offering, bringing its cash balance to more than $50 million and extending its operational runway into the second half of 2027, a position that supports the planned clinical readouts and regulatory milestones that could influence its future revenue potential and competitive standing in retinal gene therapy.
The most recent analyst rating on (IRD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
On December 17, 2025, Viatris Inc., the commercialization partner for Phentolamine Ophthalmic Solution 0.75% (Phentolamine), filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval of Phentolamine as a treatment for presbyopia. The submission, backed by positive efficacy, safety, and durability data from the VEGA-3 Phase 3 trial that confirmed earlier VEGA-2 results, marks a key regulatory step that could expand Phentolamine’s commercial prospects in the presbyopia market, though there remains uncertainty over if and when the FDA will accept and review the application.
The most recent analyst rating on (IRD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.